Nazaré brings together KOLs who are knowledgeable of the pharma product lifecycle.
Inizio Engage, a strategic, commercial, and creative engagement partner that specializes in healthcare, has launched Nazaré, a new learning and capability brand. Nazaré brings together 150+ experts in learning, life sciences, creativity, technology, and behavioral science.
The new global learning and capability brand will be part of the experience design (XD) specialist area within Inizio Engage. This means Nazaré will draw on the rest of Inizio Engage XD’s in-house creative and executional capabilities in live events, environments, film, digital, and immersive technologies, as well as considering learning experience design more holistically alongside employee engagement.
Nazaré brings together Axiom, Cormis, Logicearth Learning Services, and Ashfield Excellence Academy under one brand to support global organizations with various learning and capability programs, with knowledge in end-to-end life sciences learning support for pharmaceutical and biotech companies across the product lifecycle.
“Business leaders need evidence-based learning strategies and programs that inspire real behavior change,” says Russ Lidstone, president, Inizio Engage XD. “Nazaré provides a unique combination of learning, capability development, technology, creativity, and behavioral science to create learning that delivers real-world results.”
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.